Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
VT-3989 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
VT-3989: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ART-6043 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
ART-6043: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BC3195 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
BC3195: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CD20-targeted CAR T cell therapy (Mustang Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
CD20-targeted CAR T cell therapy (Mustang Bio): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
INO-5401 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
INO-5401: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BKR-017 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
BKR-017: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NVD-X3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
NVD-X3: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SPK-8011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
SPK-8011: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CD5 CAR T cells(Beijing GoBroad Hospital/Beijing Boren Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
CD5 CAR T cells(Beijing GoBroad Hospital/Beijing Boren Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
iNeo-Vac-P01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
iNeo-Vac-P01: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Decoy20 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Decoy20: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ExPEC10V Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
ExPEC10V: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.